Titan Pharmaceuticals (TTNP) 10-Q 14 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 11, 2019
Document and Entity Information
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	TITAN PHARMACEUTICALS INC
Entity Central Index Key	0000910267
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Trading Symbol	TTNP
Entity Common Stock, Shares Outstanding		55,549,885
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Small Business	true

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 921	$ 9,295
Restricted cash	0	361
Receivables	775	1,737
Inventory	1,309	1,262
Contract assets	0	99
Prepaid expenses and other current assets	941	547
Total current assets	3,946	13,301
Property and equipment, net	752	794
Operating lease right-of-use asset	456	0
Deferred offering costs	150	0
Total assets	5,304	14,095
Current liabilities:
Accounts payable	1,383	1,526
Accrued clinical trials expenses	434	620
Accrued sales allowances	750	0
Other accrued liabilities	653	466
Deferred revenue	0	313
Operating lease liability, current	262	0
Current portion of long-term debt	0	527
Total current liabilities	3,482	3,452
Operating lease liability, non-current	222	0
Long-term debt	3,872	3,787
Warrant liability	388	0
Derivative liability	0	25
Total liabilities	7,964	7,264
Stockholders' (deficit) equity:
Common stock, $0.001 par value per share: 125,000 shares authorized; 17,114 and 13,010 shares issued and outstanding at September 30, 2019 and December 31, 2018	17	13
Additional paid-in capital	342,419	339,397
Accumulated deficit	(345,096)	(332,579)
Total stockholders' (deficit) equity	(2,660)	6,831
Total liabilities and stockholders' (deficit) equity	$ 5,304	$ 14,095

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2019	Dec. 31, 2018
CONDENSED BALANCE SHEETS
Common Stock, Shares Authorized	125,000	125,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock shares, issued	17,114	13,010
Common Stock shares, Outstanding	17,114	13,010

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / sharesshares
Revenues:
Total revenues	$ 947	$ 1,650	$ 2,394	$ 5,381
Operating expenses:
Cost of goods sold	188	178	738	248
Research and development	1,619	1,910	5,370	5,623
Selling, general and administrative	3,023	1,514	9,336	4,508
Total operating expenses	4,830	3,602	15,444	10,379
Loss from operations	(3,883)	(1,952)	(13,050)	(4,998)
Other income (expense):
Interest expense, net	(238)	(227)	(737)	(650)
Gain on debt extinguishment, net	291	0	226	0
Non-cash gain on changes in fair value	1,041	141	1,066	141
Other expense, net	(14)	(7)	(22)	(12)
Other income (expense), net	1,080	(93)	533	(521)
Net loss and comprehensive loss	(2,803)	(2,045)	(12,517)	(5,519)
Deemed dividend on trigger of down round provision	0	(285)	0	(285)
Net loss and comprehensive loss attributable to common stockholders	$ (2,803)	$ (2,330)	$ (12,517)	$ (5,804)
Basic net loss per share | $ / shares	$ (0.18)	$ (0.64)	$ (0.89)	$ (1.62)
Diluted net loss per share | $ / shares	$ (0.18)	$ (0.68)	$ (0.89)	$ (1.66)
Weighted-average shares for basic and diluted net loss per share | shares	15,517	3,650	14,112	3,573
License revenue
Revenues:
Total revenues	$ 0	$ 1,406	$ 313	$ 5,063
Product revenue
Revenues:
Total revenues	190	244	811	318
Grant revenue
Revenues:
Total revenues	$ 757	$ 0	$ 1,270	$ 0

CONDENSED STATEMENTS OF STOCKHO

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	At-the-market offerings [Member]Common Stock [Member]	At-the-market offerings [Member]Additional Paid-In Capital [Member]	At-the-market offerings [Member]Accumulated Deficit [Member]	At-the-market offerings [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017					$ 0	$ 4	$ 324,124	$ (323,271)	$ 857
Balance (in shares) at Dec. 31, 2017						3,534
Net loss					0	$ 0	0	(2,605)	(2,605)
Issuance of warrants to purchase common stock, net					0	0	470	0	470
Stock-based compensation					0	0	432	0	432
Balance at Mar. 31, 2018					0	$ 4	325,026	(325,876)	(846)
Balance (in shares) at Mar. 31, 2018						3,534
Balance at Dec. 31, 2017					0	$ 4	324,124	(323,271)	857
Balance (in shares) at Dec. 31, 2017						3,534
Net loss									(5,519)
Balance at Sep. 30, 2018					0	$ 7	334,557	(329,075)	5,489
Balance (in shares) at Sep. 30, 2018						6,561
Balance at Mar. 31, 2018					0	$ 4	325,026	(325,876)	(846)
Balance (in shares) at Mar. 31, 2018						3,534
Net loss					0	$ 0	0	(869)	(869)
Stock-based compensation					0	0	402	0	402
Balance at Jun. 30, 2018					0	$ 4	325,428	(326,745)	(1,313)
Balance (in shares) at Jun. 30, 2018						3,534
Net loss					0	$ 0	0	(2,045)	(2,045)
Issuance of warrants to purchase common stock, net					0	0	51	0	51
Issuance of stock					0	$ 1	1,127	0	1,128
Issuance of stock (in shares)						850
Issuance of preferred stock, net					$ 0		7,280	0	7,280
Issuance of preferred stock, net (in shares)					8
Issuance of common stock upon conversion of preferred stock, net					$ 0	$ 2	(2)	0	0
Issuance of common stock upon conversion of preferred stock, net (in shares)					(8)	2,177
Stock-based compensation					$ 0	$ 0	388	0	388
Deemed dividend resulting from down round provision					0	0	285	(285)	0
Balance at Sep. 30, 2018					$ 0	$ 7	334,557	(329,075)	5,489
Balance (in shares) at Sep. 30, 2018						6,561
Balance at Dec. 31, 2018						$ 13	339,397	(332,579)	6,831
Balance (in shares) at Dec. 31, 2018						13,010
Net loss						$ 0	0	(4,517)	(4,517)
Issuance of common stock upon exercises of warrants, net						$ 0	605	0	605
Issuance of common stock upon exercises of warrants, net (in shares)						404
Stock-based compensation						$ 0	136	0	136
Balance at Mar. 31, 2019						$ 13	340,138	(337,096)	3,055
Balance (in shares) at Mar. 31, 2019						13,414
Balance at Dec. 31, 2018						$ 13	339,397	(332,579)	6,831
Balance (in shares) at Dec. 31, 2018						13,010
Net loss									(12,517)
Balance at Sep. 30, 2019						$ 17	342,419	(345,096)	(2,660)
Balance (in shares) at Sep. 30, 2019						17,114
Balance at Mar. 31, 2019						$ 13	340,138	(337,096)	3,055
Balance (in shares) at Mar. 31, 2019						13,414
Net loss						$ 0	0	(5,197)	(5,197)
Issuance of common stock upon exercises of warrants, net						$ 0	105	0	105
Issuance of common stock upon exercises of warrants, net (in shares)						70
Issuance of common stock upon conversion of convertible loan						$ 1	649	0	650
Issuance of common stock upon conversion of convertible loan, (in shares)						448
Issuance of stock	$ 0	$ 466	$ 0	$ 466
Issuance of stock (in shares)	330
Stock-based compensation						$ 0	350	0	350
Balance at Jun. 30, 2019						$ 14	341,708	(342,293)	(571)
Balance (in shares) at Jun. 30, 2019						14,262
Net loss						$ 0	0	(2,803)	(2,803)
Issuance of common stock upon exercises of warrants, net						$ 1	12	0	13
Issuance of common stock upon exercises of warrants, net (in shares)						1,372
Issuance of stock						$ 2	571	0	573
Issuance of stock (in shares)						1,480
Stock-based compensation						$ 0	128	0	128
Balance at Sep. 30, 2019						$ 17	$ 342,419	$ (345,096)	$ (2,660)
Balance (in shares) at Sep. 30, 2019						17,114

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (12,517)	$ (5,519)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization	186	337
Non-cash interest expense	467	331
Non-cash gain on inventory received from termination of license agreement	0	(1,293)
Non-cash gain on changes in fair value	(1,066)	(141)
Stock-based compensation	614	1,222
Other	(262)	0
Changes in operating assets and liabilities:
Receivables	962	(617)
Prepaid expenses and other assets	(492)	(181)
Accounts payable and other liabilities	(111)	112
Accrued sales allowances	750	0
Deferred revenue	(313)	626
Net cash used in operating activities	(11,782)	(5,123)
Cash flows from investing activities:
Purchases of property and equipment	(144)	(71)
Net cash used in investing activities	(144)	(71)
Cash flows from financing activities:
Net proceeds from the exercises of common stock warrants	724	0
Net proceeds from equity offerings	2,467	8,459
Proceeds from long-term debt	0	640
Payments of long-term debt	0	(3,000)
Net cash provided by financing activities	3,191	6,099
Change in cash, cash equivalents and restricted cash	(8,735)	905
Cash, cash equivalents and restricted cash at beginning of period	9,656	7,883
Cash, cash equivalents and restricted cash at end of period	921	8,788
Supplemental disclosure of cash flow information:
Interest paid	328	344
Warrants issued	0	6,348
Derivatives issued	0	158
Deemed dividend on trigger of down round provision	0	285
Schedule of non-cash transactions
Restricted cash	0	361
Cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 9,656	$ 7,883

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Organization and Summary of Significant Accounting Policies
Organization and Summary of Significant Policies	1. Organization and Summary of Significant Accounting Policies The Company We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. We have been transitioning to a commercial stage enterprise following the reacquisition of Probuphine® (buprenorphine) implant, or Probuphine, on May 25, 2018 from our former licensee. Probuphine is the first product based on our ProNeura technology approved in the U.S., Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder, or OUD, in select patients. We operate in only one business segment, the development and commercialization of pharmaceutical products. In January 2019, pursuant to prior stockholder authorization, our board of directors (the “Board”) effected a reverse split of the outstanding shares of our common stock at a ratio of one share for every six shares then outstanding (the “Reverse Split”). Pursuant to their respective terms, the number of shares underlying our outstanding options and warrants was reduced and their respective exercise prices increased by the Reverse Split ratio. The number of shares of common stock authorized and the par value of $0.001 per share did not change as a result of the Reverse Split. All share and per share amounts contained in this Form 10‑Q give retroactive effect to the Reverse Split. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019, or any future interim periods. The balance sheet at December 31, 2018 is derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals, Inc. Annual Report on Form 10‑K/A for the year ended December 31, 2018, as filed with the Securities and Exchange Commission (“SEC”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. The accompanying financial statements have been prepared assuming we will continue as a going concern. In October 2019, we received gross proceeds of approximately $9.1 million from the sale of 40,276,000 shares of our common stock and warrants to purchase 40,276,000 shares of our common stock in a public offering (see Note 7). As of September 30, 2019, we had cash and cash equivalents of approximately $0.9 million, which, we believe, together with the proceeds from the public offering, is sufficient to fund our planned operations into the third quarter of 2020. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful. Going concern assessment We assess going concern uncertainty in our condensed financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the “look-forward period” as defined by Accounting Standard Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15. Based upon the above assessment, we concluded that at the date of filing the financial statements in this Quarterly Report on Form 10-Q for the nine months ended September 30, 2019, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there is substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued. Use of Estimates The preparation of these unaudited condensed financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to warrants issued in equity financing, research and development expenses, income taxes, inventories, revenues, contingencies and litigation and share-based compensation. We base our estimates on historical experience, information received from third parties and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ significantly from those estimates under different assumptions or conditions. Revenue Recognition We generate revenue principally from the sale of Probuphine in the U.S., collaborative research and development arrangements, technology licenses and sales, and government grants. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation. Net Product Revenue We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue is subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration is estimated using the most-likely amount method, which is the single most-likely outcome under a contract and is typically at stated contractual rates. The actual outcome of this variable consideration may materially differ from our estimates. From time to time, we will adjust our estimates of this variable consideration when trends or significant events indicate that a change in estimate is appropriate to reflect the actual experience. Additionally, we will continue to assess the estimates of our variable consideration as we continue to accumulate additional historical data. Changes in the estimates of our variable consideration could materially affect our financial statements. Returns – Consistent with the provisions of ASC 606, we estimate returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which may impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement. During the nine months ended September 30, 2019, we entered into agreements with large national specialty pharmacies with a distribution channel different from that of our existing customers and, therefore, the related reserves have unique considerations. We will continue to evaluate the activities with these specialty pharmacies during upcoming quarters and will update the related reserves accordingly. Rebates – Our provision for rebates is estimated based on our customers’ contracted rebate programs and our historical experience of rebates paid. Discounts –The provision is estimated based upon invoice billings, utilizing historical customer payment experience. The following table provides a summary of activity with respect to our product returns, and discounts and rebates, which are included on our condensed consolidated balance sheets within accrued sales allowances (in thousands): Product Discounts and Returns Rebates Allowance Allowance Total Balance at December 31, 2018 $ 33 $ 48 $ 81 Provision 681 189 870 Payments/credits (50) (151) (201) Balance at September 30, 2019 $ 664 $ 86 $ 750 Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process. We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer’s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services. Transaction Price We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation. At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied). Allocation of Consideration As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach. Timing of Recognition Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method. Research and Development Costs and Related Accrual Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization (“CRO”) activities, sponsored research studies, product registration, patent application and prosecution, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Leases In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update, or ASU, No. 2016‑02, Leases (Topic 842) , to enhance the transparency and comparability of financial reporting related to leasing arrangements. We adopted the standard effective January 1, 2019. We determine whether the arrangement is or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on our condensed balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. We no longer recognize deferred rent on our condensed balance sheet. Recent Accounting Pronouncements Accounting Standards Adopted In February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842) . Topic 842 requires most lessees to recognize right of use assets and lease liabilities, but recognize expenses in a manner similar with current accounting standards. Effective January 1, 2019, we adopted the provisions under Topic 842 using a modified retrospective transition approach without adjusting comparative periods. Additionally, as permitted by Topic 842, we elected to apply the following practical expedients: (i) not to reassess whether any expired or existing contracts are or contain leases or the classification of any expired or existing leases and (ii) not to apply the recognition requirements to short-term leases. As a result of this adoption, we recorded operating lease right-of-use asset and operating lease liability associated with our office lease in our condensed balance sheet as of March 31, 2019. We used a discount rate of 12%, which reflects our borrowing rate as of the adoption date, to measure the present value of future lease payments to determine the fair value of our operating lease right-of-use asset and liability. Our office lease expires in June 2021 and we did not include an estimated renewal in the calculation of our operating lease right-of-use asset and liability as we believe that it is less than probable we will renew our office lease. Our adoption of Topic 842 did not result in any cumulative adjustment to the balance of our accumulated deficit as of January 1, 2019. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term, which is consistent with Topic 840. The following table presents maturities of our operating lease (in thousands): 2019 (3 months) $ 76 2020 308 2021 155 Total minimum lease payments (base rent) 539 Less: imputed interest (55) Total operating lease liabilities $ 484 In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which aligns the accounting for share-based payment awards issued to nonemployees with the guidance applicable to grants to employees. Under the new standard, equity-classified share-based payment awards issued to nonemployees are measured on the grant date, instead of the current requirement to remeasure the awards through the performance completion date. We adopted ASU 2018-07 during the three months ended March 31, 2019 using the prospective approach. The adoption of ASU 2018-07 did not have any material impact to our condensed financial statements. In August 2018, the SEC published Release No. 33-10532, Disclosure Update and Simplification, or DUSTR, which adopted amendments to certain disclosure requirements that have become redundant, duplicative, overlapping, outdated or superseded, in light of other SEC disclosure requirements, GAAP, or changes in the information environment. While most of the DUSTR amendments eliminate updated or duplicative disclosure requirements, the final rule amends the interim financial statement requirements to include a reconciliation of changes in stockholders’ equity (deficit) in the notes or as a separate statement for each period for which a statement of comprehensive income (loss) is required to be filed. The new interim reconciliation of changes in stockholders’ equity (deficit) for the three and nine months ended September 30, 2019 and 2018 is included herein. Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses , which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The amendments in this ASU are effective for us in our interim period ending March 31, 2020. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement , which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB's disclosure framework project. The ASU is effective for us in our interim period ending March 31, 2020, with early adoption permitted. We do not expect the adoption of this ASU to have any significant impact on our quarterly or annual disclosures. In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that Is a Service Contract . The ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Adoption of the ASU is either retrospective or prospective. The ASU is effective for us in our interim period ending March 31, 2020, with early adoption permitted. We are currently evaluating the impact of the adoption of ASU No. 2018-15 on our condensed financial statements. Subsequent Events We have evaluated events that have occurred after September 30, 2019 and through the date that our condensed financial statements are issued. See Note 7, “Subsequent Events.” Fair Value Measurements Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, approximate their fair values due to the short-term nature of these instruments. Our investments in money market funds are classified within Level 1 of the fair value hierarchy. Our warrant and derivative liabilities are classified within level 3 of the fair value hierarchy because the fair value is calculated using significant judgment based on our own assumptions in the valuation of these liabilities. At September 30, 2019 and December 31, 2018, the fair value of our investments in money market funds were approximately $0.8 million and approximately $8.9 million, respectively, which are included within our cash and cash equivalents in our condensed balance sheets.

Stock Plans

Stock Plans	9 Months Ended
	Sep. 30, 2019
Stock Plans
Stock Plans	2. Stock Plans In January 2019, our stockholders approved an amendment to the Titan Pharmaceuticals, Inc. 2015 Omnibus Equity Incentive Plan to increase the number of shares authorized for awards thereunder from 583,334 to 1,666,667. In January 2019, our stockholders approved a repricing of 122,115 fully-vested stock options with exercise prices in excess of $21.00 held by employees and consultants other than the named executive officers or members of the Board. The effected options were repriced at $1.55. As a result of the repricing of these stock options, we incurred a total of approximately $136,000 of additional stock-based compensation expense during the nine months ended September 30, 2019, of which approximately $77,000 was recorded within research and development and approximately $59,000 within selling, general and administrative in our condensed statement of operations and comprehensive loss. The following table summarizes the stock-based compensation expense recorded for awards under our stock option plans (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Research and development $ — $ 136 $ 91 $ 455 Selling, general and administrative 128 252 523 767 Total stock-based compensation $ 128 $ 388 $ 614 $ 1,222 We use the Black-Scholes-Merton option-pricing model with the following assumptions to estimate the fair value of our stock options: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Weighted-average risk-free interest rate — % 2.9 % 2.2 % 2.7 % Expected dividend payments — — — — Expected holding period (years) 1 — 6.4 5.4 6.4 Weighted-average volatility factor 2 — 0.91 0.94 0.89 Estimated forfeiture rates for options granted 3 — % 25 % 21 % 26 % (1) Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior. (2) Weighted average volatility is based on the historical volatility of our common stock. (3) Estimated forfeiture rates are based on historical data. The following table summarizes option activity: Weighted Weighted Average Average Remaining Aggregate Exercise Option Intrinsic Options (in Price per Term (in Value (in thousands) share years) thousands) Outstanding at January 1, 2019 665 $ 17.94 $ 4.0 Granted 854 1.64 Cancelled (274) 21.32 Outstanding at September 30, 2019 1,245 6.02 — Exercisable at September 30, 2019 705 9.41 As of September 30, 2019, there was approximately $0.3 million of total unrecognized compensation expense related to non-vested stock options. This expense was expected to be recognized over a weighted-average period of approximately 1.7 years.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2019
Net Loss Per Share
Net Loss Per Share	3. Net Loss Per Share Basic net loss per share excludes the effect of dilution and is computed by dividing net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the warrant liability (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method. The following table sets forth the reconciliation of the numerator and denominator used in the computation of basic and diluted net loss per common share: Three Months Ended Nine Months Ended September 30, September 30, (in thousands, except per share amounts) 2019 2018 2019 2018 Numerator: Net loss attributable to common stockholders for basic earnings per share $ (2,803) $ (2,330) $ (12,517) $ (5,804) Less change in fair value of derivatives — (141) — (141) Net loss used for diluted earnings per share $ (2,803) $ (2,471) $ (12,517) $ (5,945) Denominator: Basic weighted-average common shares outstanding 15,517 3,650 14,112 3,573 Diluted weighted-average common shares outstanding 15,517 3,650 14,112 3,573 Net loss per common share: Basic $ (0.18) $ (0.64) $ (0.89) $ (1.62) Diluted $ (0.18) $ (0.68) $ (0.89) $ (1.66) The table below presents common shares underlying stock options, warrants and convertible loans (see Note 5) that are excluded from the calculation of the weighted average number of common shares outstanding used for the calculation of diluted net loss per common share. These are excluded from the calculation due to their anti-dilutive effect (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Weighted-average anti-dilutive common shares resulting from options 1,282 3,531 1,027 3,396 Weighted-average anti-dilutive common shares resulting from warrants 5,961 1,461 1,222 1,618 Anti-dilutive common shares resulting from convertible loans 330 — 332 — 7,573 4,992 2,581 5,014

Molteni Purchase Agreement

Molteni Purchase Agreement	9 Months Ended
	Sep. 30, 2019
Molteni Purchase Agreement
Molteni Purchase Agreement	4. Molteni Purchase Agreement On March 21, 2018, we entered into a purchase agreement (“Molteni Purchase Agreement”) with L. Molteni & C. Dei Frattelli Alitti Società Di Esercizio S.P.A. (“Molteni”) pursuant to which Molteni acquired the European intellectual property related to Probuphine, including the marketing authorization application under review by the European Medicines Agency (“EMA”), and gained the exclusive right to commercialize the Probuphine product supplied by us in the EU, as well as certain countries of the Commonwealth of Independent States, the Middle East and North Africa (the “Molteni Territory”). We received an initial payment of €2.0 million (approximately $2.4 million) for the purchased assets and will receive additional potential payments upon achievement of certain regulatory and product label milestones. Additionally, we are entitled to receive earn-out payments for up to 15 years on net sales of Probuphine in the Molteni Territory in percentages ranging from the low-teens to the mid-twenties. We concluded that the performance obligations identified in the Molteni Purchase Agreement included the transfer of the intellectual property and our efforts towards an approval by the EMA and other regulatory bodies. The initial payment was allocated between the property transfer and our EMA efforts as set forth below. We used the expected cost-plus approach to estimate the standalone selling price of approximately $1.4 million related to our efforts towards an approval by the EMA and other regulatory bodies (“Titan Services”). This includes employee related expenses as well as other manufacturing, regulatory and clinical costs, which are incurred as part of our efforts. As of March 31, 2019, we fully recognized the revenue associated with the Titan Services under the Molteni Purchase Agreement as we completed the Titan Services. The following table presents changes in contract assets and liabilities during the nine months ended September 30, 2019 (in thousands): Beginning Ending Balance Deductions Balance Contract assets $ 99 $ (99) $ — Contract liability: Deferred revenue $ 313 $ (313) $ — In August 2018, we entered into an amendment to the Molteni Purchase Agreement, pursuant to which Molteni made an immediate payment of €950,000 (approximately $1.1 million) and a convertible loan of €550,000 (approximately $0.6 million) (“Molteni Convertible Loan”) (see Note 5) to us, both in exchange for the elimination of an aggregate of €2.0 million (approximately $2.3 million) of regulatory milestones provided for in the Molteni Purchase Agreement. We concluded that the approximately $1.1 million immediate payment by Molteni reflected a milestone payment with no additional obligations to us and, therefore, was recognized as revenue during the year ended December 31, 2018. In September 2019, we entered into an additional amendment to the Molteni Purchase Agreement, pursuant to which the percentage earn-out payments on net sales from the original range of low-teens to mid-twenties to low-teens to mid-teens. We also agreed to delay payments of any earn-outs until the later of (i) January 1, 2021 or (ii) the one year anniversary of completion of compliance by our manufacturer with EU requirements (currently anticipated to occur by the end of this year). The milestone payments under the Purchase Agreement remain unchanged.

Debt Agreements

Debt Agreements	9 Months Ended
	Sep. 30, 2019
Debt Agreements
Debt Agreements	5. Debt Agreements Horizon and Molteni Loan In July 2017, we entered into a venture loan and security agreement that was subsequently amended in February 2018, (“Horizon Loan Agreement”) with Horizon Technology Finance Corporation (“Horizon”).In connection with the Horizon Loan Agreement, we issued Horizon warrants that are currently exercisable to purchase an aggregate of 366,668 shares of our common stock at an exercise price per share of $1.50. In March 2018, we entered into an Amended and Restated Venture Loan and Security Agreement (the “Restated Loan Agreement”) with Horizon and Molteni pursuant to which Horizon assigned approximately $2.4 million of the $4.0 million outstanding principal balance of the loan to Molteni and Molteni was appointed as the collateral agent and assumed majority and administrative control of the loan. Under the Restated Loan Agreement, Molteni had the right to convert its portion of the debt into shares of our common stock at a conversion price of $7.20 per share and was required to effect this conversion of debt to equity if we complete an equity financing resulting in gross proceeds of at least $10.0 million at a price per share of common stock in excess of $7.20 and repay the $1.6 million balance of Horizon’s loan amount. In connection with the Restated Loan Agreement, we issued warrants to purchase an aggregate of 6,667 shares of our common stock with an exercise price per share of $7.20 to Horizon. In consideration of Molteni’s entry into the Restated Loan Agreement and the Purchase Agreement, on March 21, 2018, we entered into a rights agreement (the “Rights Agreement”) with Molteni pursuant to which we agreed to (i) issue Molteni seven-year warrants to purchase 90,000 shares of our common stock at an exercise price of $7.20 per share (the “Molteni Warrants”), (ii) provide Molteni customary demand and piggy-back registration rights with respect to the shares of common stock issuable upon conversion of its loan and exercise of the Molteni Warrants, (iii) designate one member of our board of directors following conversion of the loan in full and (iv) provide board observer rights to Molteni if it has not designated a board nominee as well as certain information rights. In September 2019, we entered into an amendment to the Restated Loan Agreement pursuant to which the interest-only payment and forbearance periods were extended by one year to December 31, 2020 and the maturity date was extended by one year to June 1, 2022. In connection with the amendment to the Restated Loan Agreement, the final payments to the lenders were increased by an aggregate of approximately $0.3 million (exclusive of a restructuring fee payable to Horizon) and the conversion provisions related to Molteni’s portion of the loan amount were revised to eliminate the mandatory conversion feature, to reduce the conversion price to $0.225 and to cap the number of shares issuable upon conversion to 3,422,777. As of September 30, 2019, the loan from Molteni under the amendment to the Restated Loan Agreement was convertible into 3,422,777 shares of our common stock. In accordance with ASC 470, "Debt," the amendment to the loan from Molteni is accounted for under debt extinguishment accounting, which required us to extinguish the carrying amount of the loan prior to the amendment and reacquire the loan after the amendment. As a result, during the three months ended September 30, 2019, we recorded approximately $0.3 million gain on debt extinguishment related to the write-off of the balance of the accreted final payment of the loan. The modification to the loan from Horizon did not constitute debt extinguishment and, therefore, did not have any impact to our condensed financial statements. Molteni Convertible Loan In connection with the Amendment to the Molteni Purchase Agreement (see Note 4), in June 2019, the Molteni Convertible Loan, together with unpaid accrued interest, was converted in full into 448,287 shares of our common stock at $1.50 per share upon the receipt of EMA approval of Sixmo. As a result, we recorded approximately $0.1 million loss on debt extinguishment.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity
Stockholders' Equity (Deficit)	6. Stockholders’ Equity At-the-Market Offering (the “ATM”) In April 2019, we implemented the ATM for the sale of up to $8.6 million of our common stock. During the three months ended June 30, 2019, we issued a total of 329,656 shares of our common stock at a weighted-average price of $1.60 per share for total net proceeds of approximately $0.5 million under the ATM. In August 2019, we reduced the dollar amount that can be sold under ATM to $4.0 million. August 2019 Offering In August 2019, we completed an offering (the “August 2019 Offering”) with a single accredited institutional investor (the “Purchaser”) pursuant to which we issued 1,480,000 shares of our common stock and pre-funded warrants to purchase 1,372,314 shares of our common stock with an exercise price of $0.01 per share (the “Pre-funded Warrants”) in a registered direct offering and warrants to purchase 2,852,314 shares of our common stock with an exercise price of $1.07 per share (the “Placement Warrants”) in a concurrent private placement. The Pre-Funded Warrants, which were exercised for common stock in September 2019, were issued in lieu of common stock in order to ensure the Purchaser did not exceed certain beneficial ownership limitations. The Placement Warrants will become exercisable in February 2020 and will expire in February 2025. The Placement Warrants agreement contains a provision where the warrant holder has the option to receive cash, equal to the Black Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). As a result of this provision, in accordance with ASC 480, “Distinguishing Liabilities from Equity,” the Placement Warrants are required to be classified as liabilities. The fair value of the Placement Warrants is determined using the Black-Scholes Option Pricing model to calculate the call option and Binomial Option Pricing model to calculate the put option with changes in the fair value recorded in the condensed statements of operations and comprehensive loss. During the three months ended September 30, 2019, approximately $1.4 million and approximately $0.6 million, respectively, were allocated to warrant liability and additional paid-in capital. The warrant liability associated with the Placement Warrants is classified within level 3 of the fair value hierarchy. The below table represents the weighted-average key assumptions used to calculate the fair value of the Placement Warrants: As of August 7, September 30, 2019 2019 Volatility 87 % 97 % Risk-free Interest Rate 1.5 % 1.6 % Dividend Rate — — Expected Term (in years) 4.9 4.8 Weighted-Average Fair Value per share warrant $ 0.50 $ 0.14 The below table presents the roll-forward of the warrant liability associated with the Placement Warrants (in thousands): Beginning balance as of January 1, 2019 $ — Warrant liability 1,429 Non-cash gain on changes in fair value 1 (1,041) Ending balance as of September 30, 2019 $ 388 (1) Recorded within other income in the condensed statements of operations and comprehensive loss for the three and nine months ended September 30, 2019. (2)

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events
Subsequent Events	7. Subsequent Events In October 2019, we completed an underwritten public offering (the “Public Offering”) pursuant to which we issued 40,276,000 units at an offering price of $0.225 per unit, consisting of 35,886,000 shares of our common stock and pre-funded warrants to purchase 4,390,000 shares of our common stock with an exercise price of $0.01 per share (the “Pre-funded Warrants"), and Class B Warrants to purchase 40,276,000 shares of our common stock at $0.225 per share (the “Class B Warrants”). The Pre-Funded Warrants, which were exercised for common stock in October 2019, were issued in lieu of common stock in order to ensure the Purchaser did not exceed certain beneficial ownership limitations. The Class B Warrants are immediately exercisable and will expire in October 2024. The Class B Warrant agency agreement contains a provision where the warrant holder has the option to receive cash equal to the Black Scholes fair value of the remaining unexercised portion of the warrant in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Through the date of filing this Quarterly Report on Form 10-Q, we received net cash proceeds of approximately $8.1 million, after deduction of underwriting fees and other offering expenses.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Organization and Summary of Significant Accounting Policies
The Company	The Company We are a pharmaceutical company developing therapeutics utilizing our proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. We have been transitioning to a commercial stage enterprise following the reacquisition of Probuphine® (buprenorphine) implant, or Probuphine, on May 25, 2018 from our former licensee. Probuphine is the first product based on our ProNeura technology approved in the U.S., Canada and the European Union, or EU, for the maintenance treatment of opioid use disorder, or OUD, in select patients. We operate in only one business segment, the development and commercialization of pharmaceutical products. In January 2019, pursuant to prior stockholder authorization, our board of directors (the “Board”) effected a reverse split of the outstanding shares of our common stock at a ratio of one share for every six shares then outstanding (the “Reverse Split”). Pursuant to their respective terms, the number of shares underlying our outstanding options and warrants was reduced and their respective exercise prices increased by the Reverse Split ratio. The number of shares of common stock authorized and the par value of $0.001 per share did not change as a result of the Reverse Split. All share and per share amounts contained in this Form 10‑Q give retroactive effect to the Reverse Split.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10‑Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statement presentation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019, or any future interim periods. The balance sheet at December 31, 2018 is derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in the Titan Pharmaceuticals, Inc. Annual Report on Form 10‑K/A for the year ended December 31, 2018, as filed with the Securities and Exchange Commission (“SEC”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. The accompanying financial statements have been prepared assuming we will continue as a going concern. In October 2019, we received gross proceeds of approximately $9.1 million from the sale of 40,276,000 shares of our common stock and warrants to purchase 40,276,000 shares of our common stock in a public offering (see Note 7). As of September 30, 2019, we had cash and cash equivalents of approximately $0.9 million, which, we believe, together with the proceeds from the public offering, is sufficient to fund our planned operations into the third quarter of 2020. We will require additional funds to finance our operations. We are exploring several financing alternatives; however, there can be no assurance that our efforts to obtain the funding required to continue our operations will be successful.
Going concern assessment	Going concern assessment We assess going concern uncertainty in our condensed financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the “look-forward period” as defined by Accounting Standard Update (“ASU”) No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15. Based upon the above assessment, we concluded that at the date of filing the financial statements in this Quarterly Report on Form 10-Q for the nine months ended September 30, 2019, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there is substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued
Use of Estimates	Use of Estimates The preparation of these unaudited condensed financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to warrants issued in equity financing, research and development expenses, income taxes, inventories, revenues, contingencies and litigation and share-based compensation. We base our estimates on historical experience, information received from third parties and on various market specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ significantly from those estimates under different assumptions or conditions.
Revenue Recognition	Revenue Recognition We generate revenue principally from the sale of Probuphine in the U.S., collaborative research and development arrangements, technology licenses and sales, and government grants. Consideration received for revenue arrangements with multiple components is allocated among the separate performance obligations based upon their relative estimated standalone selling price. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps for our revenue recognition: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation. Net Product Revenue We recognize revenue from product sales when control of the product transfers, generally upon shipment or delivery, to our customers, which include distributors. As customary in the pharmaceutical industry, our gross product revenue is subject to a variety of deductions in the forms of variable consideration, such as rebates, chargebacks, returns and discounts, in arriving at reported net product revenue. This variable consideration is estimated using the most-likely amount method, which is the single most-likely outcome under a contract and is typically at stated contractual rates. The actual outcome of this variable consideration may materially differ from our estimates. From time to time, we will adjust our estimates of this variable consideration when trends or significant events indicate that a change in estimate is appropriate to reflect the actual experience. Additionally, we will continue to assess the estimates of our variable consideration as we continue to accumulate additional historical data. Changes in the estimates of our variable consideration could materially affect our financial statements. Returns – Consistent with the provisions of ASC 606, we estimate returns at the inception of each transaction, based on multiple considerations, including historical sales, historical experience of actual customer returns, levels of inventory in our distribution channel, expiration dates of purchased products and significant market changes which may impact future expected returns to the extent that we would not reverse any receivables, revenues, or contract assets already recognized under the agreement. During the nine months ended September 30, 2019, we entered into agreements with large national specialty pharmacies with a distribution channel different from that of our existing customers and, therefore, the related reserves have unique considerations. We will continue to evaluate the activities with these specialty pharmacies during upcoming quarters and will update the related reserves accordingly. Rebates – Our provision for rebates is estimated based on our customers’ contracted rebate programs and our historical experience of rebates paid. Discounts –The provision is estimated based upon invoice billings, utilizing historical customer payment experience. The following table provides a summary of activity with respect to our product returns, and discounts and rebates, which are included on our condensed consolidated balance sheets within accrued sales allowances (in thousands): Product Discounts and Returns Rebates Allowance Allowance Total Balance at December 31, 2018 $ 33 $ 48 $ 81 Provision 681 189 870 Payments/credits (50) (151) (201) Balance at September 30, 2019 $ 664 $ 86 $ 750 Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. Our performance obligations include commercialization license rights, development services and services associated with the regulatory approval process. We have optional additional items in contracts, which are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer’s discretion are generally considered as options. We assess if these options provide a material right to the customer and, if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services. Transaction Price We have both fixed and variable consideration. Non-refundable upfront payments are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation. At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. For arrangements that include sales-based royalties or earn-out payments, including milestone payments based on the level of sales, and the license or purchase agreement is deemed to be the predominant item to which the royalties or earn-out payments relate, we recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty or earn-out payment has been allocated has been satisfied (or partially satisfied). Allocation of Consideration As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights are calculated using the residual approach. For all other performance obligations, we use a cost-plus margin approach. Timing of Recognition Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under an arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for licenses or sales of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.
Research and Development Costs and Related Accrual	Research and Development Costs and Related Accrual Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses, facility costs, administrative expenses and allocations of corporate costs. External expenses consist of costs associated with outsourced contract research organization (“CRO”) activities, sponsored research studies, product registration, patent application and prosecution, and investigator sponsored trials. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by CROs and clinical sites. These costs are recorded as a component of research and development expenses. Under our agreements, progress payments are typically made to investigators, clinical sites and CROs. We analyze the progress of the clinical trials, including levels of patient enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the accrued balance in any accounting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.
Leases	Leases In February 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standard Update, or ASU, No. 2016‑02, Leases (Topic 842) , to enhance the transparency and comparability of financial reporting related to leasing arrangements. We adopted the standard effective January 1, 2019. We determine whether the arrangement is or contains a lease at inception. Operating lease right-of-use assets and lease liabilities are recognized at the present value of the future lease payments at commencement date. The interest rate implicit in lease contracts is typically not readily determinable, and therefore, we utilize our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on our condensed balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. We no longer recognize deferred rent on our condensed balance sheet.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Standards Adopted In February 2016, the FASB issued ASU No. 2016‑02, Leases (Topic 842) . Topic 842 requires most lessees to recognize right of use assets and lease liabilities, but recognize expenses in a manner similar with current accounting standards. Effective January 1, 2019, we adopted the provisions under Topic 842 using a modified retrospective transition approach without adjusting comparative periods. Additionally, as permitted by Topic 842, we elected to apply the following practical expedients: (i) not to reassess whether any expired or existing contracts are or contain leases or the classification of any expired or existing leases and (ii) not to apply the recognition requirements to short-term leases. As a result of this adoption, we recorded operating lease right-of-use asset and operating lease liability associated with our office lease in our condensed balance sheet as of March 31, 2019. We used a discount rate of 12%, which reflects our borrowing rate as of the adoption date, to measure the present value of future lease payments to determine the fair value of our operating lease right-of-use asset and liability. Our office lease expires in June 2021 and we did not include an estimated renewal in the calculation of our operating lease right-of-use asset and liability as we believe that it is less than probable we will renew our office lease. Our adoption of Topic 842 did not result in any cumulative adjustment to the balance of our accumulated deficit as of January 1, 2019. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term, which is consistent with Topic 840. The following table presents maturities of our operating lease (in thousands): 2019 (3 months) $ 76 2020 308 2021 155 Total minimum lease payments (base rent) 539 Less: imputed interest (55) Total operating lease liabilities $ 484 In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which aligns the accounting for share-based payment awards issued to nonemployees with the guidance applicable to grants to employees. Under the new standard, equity-classified share-based payment awards issued to nonemployees are measured on the grant date, instead of the current requirement to remeasure the awards through the performance completion date. We adopted ASU 2018-07 during the three months ended March 31, 2019 using the prospective approach. The adoption of ASU 2018-07 did not have any material impact to our condensed financial statements. In August 2018, the SEC published Release No. 33-10532, Disclosure Update and Simplification, or DUSTR, which adopted amendments to certain disclosure requirements that have become redundant, duplicative, overlapping, outdated or superseded, in light of other SEC disclosure requirements, GAAP, or changes in the information environment. While most of the DUSTR amendments eliminate updated or duplicative disclosure requirements, the final rule amends the interim financial statement requirements to include a reconciliation of changes in stockholders’ equity (deficit) in the notes or as a separate statement for each period for which a statement of comprehensive income (loss) is required to be filed. The new interim reconciliation of changes in stockholders’ equity (deficit) for the three and nine months ended September 30, 2019 and 2018 is included herein. Accounting Standards Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses , which requires an organization to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. The amendments in this ASU are effective for us in our interim period ending March 31, 2020. We are currently assessing the impact of the adoption of Topic 326 on our financial statements and disclosures. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement , which eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of the FASB's disclosure framework project. The ASU is effective for us in our interim period ending March 31, 2020, with early adoption permitted. We do not expect the adoption of this ASU to have any significant impact on our quarterly or annual disclosures. In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that Is a Service Contract . The ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Adoption of the ASU is either retrospective or prospective. The ASU is effective for us in our interim period ending March 31, 2020, with early adoption permitted. We are currently evaluating the impact of the adoption of ASU No. 2018-15 on our condensed financial statements.
Subsequent Events	Subsequent Events We have evaluated events that have occurred after September 30, 2019 and through the date that our condensed financial statements are issued. See Note 7, “Subsequent Events.”
Fair Value Measurements	Fair Value Measurements Financial instruments, including receivables, accounts payable and accrued liabilities are carried at cost, approximate their fair values due to the short-term nature of these instruments. Our investments in money market funds are classified within Level 1 of the fair value hierarchy. Our warrant and derivative liabilities are classified within level 3 of the fair value hierarchy because the fair value is calculated using significant judgment based on our own assumptions in the valuation of these liabilities. At September 30, 2019 and December 31, 2018, the fair value of our investments in money market funds were approximately $0.8 million and approximately $8.9 million, respectively, which are included within our cash and cash equivalents in our condensed balance sheets

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Organization and Summary of Significant Accounting Policies
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, (in thousands, except per share amounts) 2019 2018 2019 2018 Numerator: Net loss attributable to common stockholders for basic earnings per share $ (2,803) $ (2,330) $ (12,517) $ (5,804) Less change in fair value of derivatives — (141) — (141) Net loss used for diluted earnings per share $ (2,803) $ (2,471) $ (12,517) $ (5,945) Denominator: Basic weighted-average common shares outstanding 15,517 3,650 14,112 3,573 Diluted weighted-average common shares outstanding 15,517 3,650 14,112 3,573 Net loss per common share: Basic $ (0.18) $ (0.64) $ (0.89) $ (1.62) Diluted $ (0.18) $ (0.68) $ (0.89) $ (1.66)
Summary of activity with respect to our product returns, and discounts and rebates	The following table provides a summary of activity with respect to our product returns, and discounts and rebates, which are included on our condensed consolidated balance sheets within accrued sales allowances (in thousands): Product Discounts and Returns Rebates Allowance Allowance Total Balance at December 31, 2018 $ 33 $ 48 $ 81 Provision 681 189 870 Payments/credits (50) (151) (201) Balance at September 30, 2019 $ 664 $ 86 $ 750
Schedule of maturities of operating lease	The following table presents maturities of our operating lease (in thousands): 2019 (3 months) $ 76 2020 308 2021 155 Total minimum lease payments (base rent) 539 Less: imputed interest (55) Total operating lease liabilities $ 484

Stock Plans (Tables)

Stock Plans (Tables)	9 Months Ended
	Sep. 30, 2019
Stock Plans
Schedule of stock-based compensation expense recorded for awards under our stock option plans	The following table summarizes the stock-based compensation expense recorded for awards under our stock option plans (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Research and development $ — $ 136 $ 91 $ 455 Selling, general and administrative 128 252 523 767 Total stock-based compensation $ 128 $ 388 $ 614 $ 1,222
Schedule of estimate the fair value of stock options	Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Weighted-average risk-free interest rate — % 2.9 % 2.2 % 2.7 % Expected dividend payments — — — — Expected holding period (years) 1 — 6.4 5.4 6.4 Weighted-average volatility factor 2 — 0.91 0.94 0.89 Estimated forfeiture rates for options granted 3 — % 25 % 21 % 26 % (1) Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior. (2) Weighted average volatility is based on the historical volatility of our common stock. (3) Estimated forfeiture rates are based on historical data.
Schedule of option activity	The following table summarizes option activity: Weighted Weighted Average Average Remaining Aggregate Exercise Option Intrinsic Options (in Price per Term (in Value (in thousands) share years) thousands) Outstanding at January 1, 2019 665 $ 17.94 $ 4.0 Granted 854 1.64 Cancelled (274) 21.32 Outstanding at September 30, 2019 1,245 6.02 — Exercisable at September 30, 2019 705 9.41

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Net Loss Per Share
Schedule of computation of earnings (loss) per share	Three Months Ended Nine Months Ended September 30, September 30, (in thousands, except per share amounts) 2019 2018 2019 2018 Numerator: Net loss attributable to common stockholders for basic earnings per share $ (2,803) $ (2,330) $ (12,517) $ (5,804) Less change in fair value of derivatives — (141) — (141) Net loss used for diluted earnings per share $ (2,803) $ (2,471) $ (12,517) $ (5,945) Denominator: Basic weighted-average common shares outstanding 15,517 3,650 14,112 3,573 Diluted weighted-average common shares outstanding 15,517 3,650 14,112 3,573 Net loss per common share: Basic $ (0.18) $ (0.64) $ (0.89) $ (1.62) Diluted $ (0.18) $ (0.68) $ (0.89) $ (1.66)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	These are excluded from the calculation due to their anti-dilutive effect (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Weighted-average anti-dilutive common shares resulting from options 1,282 3,531 1,027 3,396 Weighted-average anti-dilutive common shares resulting from warrants 5,961 1,461 1,222 1,618 Anti-dilutive common shares resulting from convertible loans 330 — 332 — 7,573 4,992 2,581 5,014

Molteni Purchase Agreement (Tab

Molteni Purchase Agreement (Tables)	9 Months Ended
	Sep. 30, 2019
Purchase Agreement [Abstract]
Schedule of changes in contract assets and liabilities	The following table presents changes in contract assets and liabilities during the nine months ended September 30, 2019 (in thousands): Beginning Ending Balance Deductions Balance Contract assets $ 99 $ (99) $ — Contract liability: Deferred revenue $ 313 $ (313) $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity
Fair Value Measurement Inputs and Valuation Techniques	As of August 7, September 30, 2019 2019 Volatility 87 % 97 % Risk-free Interest Rate 1.5 % 1.6 % Dividend Rate — — Expected Term (in years) 4.9 4.8 Weighted-Average Fair Value per share warrant $ 0.50 $ 0.14
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The below table presents the roll-forward of the warrant liability associated with the Placement Warrants (in thousands): Beginning balance as of January 1, 2019 $ — Warrant liability 1,429 Non-cash gain on changes in fair value 1 (1,041) Ending balance as of September 30, 2019 $ 388 (1) Recorded within other income in the condensed statements of operations and comprehensive loss for the three and nine months ended September 30, 2019.

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies - Summary of Activity Product Returns and Discounts and Rebates (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Balance at December 31, 2018	$ 81
Provision	870
Payments/credits	(201)
Balance at June 30, 2019	750
Product Returns Allowance [Member]
Balance at December 31, 2018	33
Provision	681
Payments/credits	(50)
Balance at June 30, 2019	664
Discounts and Rebates Allowance [Member]
Balance at December 31, 2018	48
Provision	189
Payments/credits	(151)
Balance at June 30, 2019	$ 86

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies - Summary of Maturities of Operating Lease (Details) $ in Thousands	Sep. 30, 2019USD ($)
Organization and Summary of Significant Accounting Policies
2019 (6 months)	$ 76
2020	308
2021	155
Total minimum lease payments (base rent)	539
Less: imputed interest	(55)
Total operating lease liabilities	$ 484

Organization and Summary of S_6

Organization and Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 31, 2019USD ($)shares	Jan. 31, 2019$ / shares	Sep. 30, 2019USD ($)segment$ / sharesshares	Sep. 30, 2018USD ($)shares	Sep. 30, 2019USD ($)$ / shares	Sep. 30, 2018USD ($)segment	Dec. 31, 2018USD ($)$ / shares
Schedule of Organization and Summary of Significant Accounting Policies
Number of Operating Segments | segment			1			1
Stockholders' Equity Note, Stock Split, Conversion Ratio		0.1667
Substantial Doubt about Going Concern, Management's Evaluation					Going concern assessmentWe assess going concern uncertainty in our condensed financial statements to determine if we have sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the financial statements are issued or available to be issued, which is referred to as the "look-forward period" as defined by Accounting Standard Update ("ASU") No. 2014-15. As part of this assessment, based on conditions that are known and reasonably knowable to us, we will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including the timing and nature of projected cash expenditures or programs, and its ability to delay or curtail expenditures or programs, if necessary, among other factors. Based on this assessment, as necessary or applicable, we make certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent we deem probable those implementations can be achieved and we have the proper authority to execute them within the look-forward period in accordance with ASU No. 2014-15.Based upon the above assessment, we concluded that at the date of filing the financial statements in this Quarterly Report on Form 10-Q for the nine months ended September 30, 2019, we did not have sufficient cash to fund our operations for the next 12 months without additional funds and, therefore, there is substantial doubt about our ability to continue as a going concern within 12 months after the date the financial statements were issued.
Cash and Cash Equivalents, at Carrying Value | $			$ 921	$ 8,427	$ 921	$ 8,427	$ 9,295
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.001	$ 0.001		$ 0.001		$ 0.001
Proceeds from sale of common stock | $					$ 2,467	$ 8,459
Accounting Standards Update 2016-02 [Member]
Schedule of Organization and Summary of Significant Accounting Policies
Lessee, Operating Lease, Discount Rate		12.00%
Fair Value, Recurring [Member] | Money Market Funds [Member]
Schedule of Organization and Summary of Significant Accounting Policies
Cash Equivalents, at Carrying Value | $			$ 800		$ 800		$ 8,900
Common Stock [Member]
Schedule of Organization and Summary of Significant Accounting Policies
Sale of common stock | shares			1,480,000	850,000
October 2019 Equity Offering | Subsequent Event
Schedule of Organization and Summary of Significant Accounting Policies
Sale of common stock | shares	40,276,000
October 2019 Equity Offering | Common Stock [Member] | Subsequent Event
Schedule of Organization and Summary of Significant Accounting Policies
Proceeds from sale of common stock | $	$ 9,100
Sale of common stock | shares	35,886,000
October 2019 Equity Offering | Common Stock [Member] | Placement Warrants [Member] | Subsequent Event
Schedule of Organization and Summary of Significant Accounting Policies
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	40,276,000

Stock Plans Stock-based compens

Stock Plans Stock-based compensation expense recorded for awards (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Total stock-based compensation expense	$ 128	$ 388	$ 614	$ 1,222
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Total stock-based compensation expense	0	136	91	455
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Total stock-based compensation expense	$ 128	$ 252	$ 523	$ 767

Stock Plans - Fair value of sto

Stock Plans - Fair value of stock options (Details) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2019		Sep. 30, 2018		Sep. 30, 2019	Sep. 30, 2018
Stock Plans
Weighted-average risk-free interest rate	0.00%		2.90%		2.20%	2.70%
Expected dividend payments	$ 0		$ 0		$ 0	$ 0
Expected holding period (years)			6 years 4 months 24 days	[1]	5 years 4 months 24 days	6 years 4 months 24 days
Weighted-average volatility factor	0.00%	[2]	0.91%	[2]	0.94%	0.89%
Estimated forfeiture rates for options granted	0.00%	[3]	25.00%	[3]	21.00%	26.00%
[1]	Expected holding period is based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and the expectations of future employee behavior.
[2]	Weighted average volatility is based on the historical volatility of our common stock.
[3]	Estimated forfeiture rates are based on historical data.

Stock Plans - Option activity (

Stock Plans - Option activity (Details) - USD ($) $ / shares in Units, shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Stock Plans
Number of Options and Awards Outstanding at Beginning of Period	665
Shares, Granted	854
Shares, Cancelled	(274)
Number of Options and Awards Outstanding at End of Period	1,245	665
Shares, Exercisable at June 30, 2019	705
Weighted Average Exercise Price, Outstanding at Beginning of Period	$ 17.94
Weighted Average Exercise Price, Granted	1.64
Weighted Average Exercise Price, Cancelled	21.32
Weighted Average Exercise Price, Outstanding at End of Period	6.02	$ 17.94
Weighted Average Exercise Price, Exercisable at June 30, 2019	$ 9.41
Weighted Average Remaining Contractual Term, Outstanding (Years)	8 years 1 month 28 days	6 years 5 months 9 days
Weighted Average Remaining Contractual Term, Exercisable at December 31, 2018	7 years 1 month 13 days
Aggregate Intrinsic Value, Outstanding at Beginning of Period	$ 4,000
Aggregate Intrinsic Value, Outstanding at End of Period		$ 4,000

Stock Plans - Additional Inform

Stock Plans - Additional Information (Details) - USD ($)	1 Months Ended	9 Months Ended
	Jan. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award
Weighted-average period for recognizing non-vested stock option		1 year 8 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	122,115
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 21
Increase In The Price In Respect Of Lower Range In Respect Of Shares Authorised Under Compensation Plan	$ 1.55
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 300,000
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,666,667		583,334
Stock Compensation Plan
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost		136,000
Stock Compensation Plan | Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost		77,000
Stock Compensation Plan | General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost		$ 59,000

Net Loss Per Share (Details) -

Net Loss Per Share (Details) - Basic and diluted net loss per common share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Numerator:
Net loss attributable to common stockholders for basic earnings per share	$ (2,803)	$ (2,330)	$ (12,517)	$ (5,804)
Less change in fair value of derivatives	0	(141)	0	(141)
Net Income (Loss) Available to Common Stockholders, Diluted	$ (2,803)	$ (2,471)	$ (12,517)	$ (5,945)
Denominator:
Basic weighted-average common shares outstanding	15,517	3,650	14,112	3,573
Diluted weighted-average common shares outstanding	15,517	3,650	14,112	3,573
Net loss per common share:
Basic	$ (0.18)	$ (0.64)	$ (0.89)	$ (1.62)
Diluted	$ (0.18)	$ (0.68)	$ (0.89)	$ (1.66)

Net Loss Per Share (Details) _2

Net Loss Per Share (Details) - Anti-dilutive common shares - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Anti-dilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,573	4,992	2,581	5,014
Convertible Debt Securities
Anti-dilutive Securities Excluded from Computation of Earnings Per Share, Amount	330	0	332
Employee Stock Option
Anti-dilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,282	3,531	1,027	3,396
Warrant
Anti-dilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,961	1,461	1,222	1,618

Molteni Purchase Agreement (Det

Molteni Purchase Agreement (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)
Purchase Agreement [Abstract]
Contract assets	$ 99
Contract with Customer, Asset Deductions	(99)
Contract with Customer, Asset	0
Deferred Revenue	313
Deferred Revenue, Deductions	(313)
Deferred Revenue	$ 0

Molteni Purchase Agreement - Ad

Molteni Purchase Agreement - Additional Information (Details) $ in Thousands	Mar. 21, 2018EUR (€)	Mar. 21, 2018USD ($)	Aug. 31, 2018EUR (€)	Aug. 31, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Aug. 31, 2018USD ($)
Purchase Agreement
Proceeds from Sale of Productive Assets	€ 2,000,000	$ 2,400
Revenue from Contract with Customer, Including Assessed Tax	€ 2,000,000	2,300	€ 950,000	$ 1,100	$ 947	$ 1,650	$ 2,394	$ 5,381
Revenue, Remaining Performance Obligation, Amount		$ 1,400
Convertible Debt			€ 550,000						$ 600
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-04-01
Purchase Agreement
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period		15 years

Debt Agreements (Details)

Debt Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2019	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Mar. 21, 2018	Jul. 31, 2017	Jul. 27, 2017
Gain on debt extinguishment, net			$ 291	$ 0	$ 226	$ 0
Long-term Debt, Current Maturities	$ 0		$ 0		$ 0		$ 527
Horizon Technology Finance Corporation
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 1.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									366,668
Molteni Loan
Conversion Price, (in dollars per share)	$ 0.225		$ 0.225		$ 0.225
Gain on debt extinguishment, net			$ 300
Long-term Debt		$ 4,000
Convertible Debt, Shares Issued upon Conversion					3,422,777
Horizon Loan
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 7.20
Conversion Price, (in dollars per share)		$ 7.20
Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares, Amount		$ 10,000
Debt Instrument, Periodic Payment		$ 1,600
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								6,667
Long-term Debt								$ 2,400
Horizon and Molteni Loan
Increase in final debt repayment to the lenders	$ 300
Molteni Purchase Agreement
Conversion Price, (in dollars per share)	$ 1.50		$ 1.50		$ 1.50
Debt Conversion, Converted Instrument, Shares Issued					448,287
New Horizon Warrants
Conversion Price, (in dollars per share)								$ 7.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								90,000

Stockholders' Equity - Measurem

Stockholders' Equity - Measurement of Fairvalue of Assets and Liabilities (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)$ / shares	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)$ / shares	Sep. 30, 2018USD ($)	Aug. 07, 2019$ / sharesUSD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance			$ 0
Warrant liability			1,429,000
Non-cash gain on changes in fair value	$ (1,041,000)	$ (141,000)	(1,066,000)	$ (141,000)
Ending balance	$ 388,000		388,000
Other Operating Income (Expense) [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Non-cash gain on changes in fair value			$ (1,041,000)
Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding	97		97		87
Risk-free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding	1.6		1.6		1.5
Dividend Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding | $ / shares	0		0		0
Expected Term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding	4.8		4.8		4.9
Weighted-Average Fair Value per share warrant
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and rights outstanding | $ / shares	0.14		0.14		0.50

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended			9 Months Ended
	Aug. 31, 2019	Apr. 30, 2019	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Sale of stock
Issuance of stock			$ 573		$ 1,128
Proceeds from sale of common stock						$ 2,467	$ 8,459
ATM
Sale of stock
Issuance of stock (in shares)				329,656
Weighted-average price				$ 1.60
Proceeds from sale of common stock		$ 500
ATM | Maximum [Member]
Sale of stock
Issuance of stock	$ 4,000	$ 8,600

Stockholders' Equity - Addition

Stockholders' Equity - Additional information - August 2019 Equity Offering (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Equity Offering
Proceeds from Issuance of Common Stock				$ 2,467	$ 8,459
Common Stock [Member]
Equity Offering
Stock Issued During Period, Shares, New Issues		1,480,000	850,000
August 2019 Equity Offering | Warrant Liability [Member]
Equity Offering
Proceeds from Issuance of Warrants		$ 1,400
August 2019 Equity Offering | Common Stock [Member]
Equity Offering
Stock Issued During Period, Shares, New Issues	1,480,000
August 2019 Equity Offering | Additional Paid-In Capital [Member]
Equity Offering
Proceeds from Issuance of Common Stock		$ 600
August 2019 Equity Offering | Pre-Funded Warrants [Member] | Common Stock [Member]
Equity Offering
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,372,314
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
August 2019 Equity Offering | Placement Warrants [Member] | Common Stock [Member]
Equity Offering
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,852,314
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.07

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Oct. 31, 2019	Sep. 30, 2019	Sep. 30, 2018
Common Stock [Member]
Subsequent Event
Stock Issued During Period, Shares, New Issues		1,480,000	850,000
Subsequent Event | October 2019 Equity Offering
Subsequent Event
Stock Issued During Period, Shares, New Issues	40,276,000
Subsequent Event | October 2019 Equity Offering | Common Stock [Member]
Subsequent Event
Stock Issued During Period, Shares, New Issues	35,886,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.225
Net Cash Proceeds From Issuance Of Common Stock After Deduction Of Underwriting Fees And Other Offering Expenses	$ 8.1
Subsequent Event | October 2019 Equity Offering | Pre-Funded Warrants [Member] | Common Stock [Member]
Subsequent Event
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,390,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Subsequent Event | October 2019 Equity Offering | Placement Warrants [Member] | Common Stock [Member]
Subsequent Event
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	40,276,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.225